Am J Perinatol
DOI: 10.1055/a-2615-5098
Original Article

Outcomes of Total Abdominal Hysterectomy Compared to Supracervical Hysterectomy for Management of Placenta Accreta Spectrum

1   Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland
,
Debra Eluobaju
1   Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland
,
Amanda Finney
2   Biostatistics, Epidemiology, and Data Management Core, Johns Hopkins University School of Medicine, Baltimore, Maryland
,
Laura Prichett
2   Biostatistics, Epidemiology, and Data Management Core, Johns Hopkins University School of Medicine, Baltimore, Maryland
,
Nicole R. Gavin
3   Department of Gynecology and Obstetrics, Division of Maternal-Fetal Medicine, University of Connecticut, Mansfield, Connecticut
,
Christopher Novak
1   Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland
,
Kristin Martin
1   Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland
,
Arthur Jason Vaught
1   Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland
› Author Affiliations

Funding None.

Abstract

Objective

Although cesarean hysterectomy (C-HYST) is standard management for placenta accreta spectrum (PAS), the type of hysterectomy performed, total abdominal (TAH), or supracervical (SCH), is left to surgeon discretion. TAH has been previously associated with higher estimated blood loss (EBL), transfusion requirements, and complications compared to SCH.

Study Design

This was a single-site retrospective cohort study examining outcomes of TAH compared to SCH for PAS performed from 2008 to 2023. PAS was confirmed by clinical and pathologic diagnoses. Cervical removal was confirmed by operative report, postoperative exam, and pathology. Associations were assessed using chi-square tests, Fisher's exact tests, Mann–Whitney U tests, or individual t-tests.

Results

During the study period, 90 TAH and 54 SCH were performed. There were no significant differences in patient demographics, except that planned C-HYST was more likely to be TAH. TAH was associated with significantly lower transfusion requirements. When unexpected hysterectomies were excluded, there was not a significant difference in blood products transfused between the TAH and SCH groups.

Conclusion

In PAS, maternal outcomes after TAH are at least equivalent to SCH. The surgical approach for the management of PAS should be further explored.

Key Points

  • In PAS, outcomes are at least equivalent between TAH and SCH.

  • C-HYST is optimally performed in a planned manner with all multidisciplinary team members present.

  • Vertical skin incision was significantly associated with TAH in this retrospective cohort study.



Publication History

Received: 28 March 2025

Accepted: 18 May 2025

Accepted Manuscript online:
19 May 2025

Article published online:
03 June 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Einerson BD, Healy AJ, Lee A, Warrick C, Combs CA, Hameed AB. Society for Maternal-Fetal Medicine (SMFM), SMFM Patient Safety and Quality Committee. Electronic address: smfm@smfm.org. Society for maternal-fetal medicine special statement: emergency checklist, planning worksheet, and system preparedness bundle for placenta accreta spectrum. Am J Obstet Gynecol 2024; 230 (01) B2-B11
  • 2 Einerson BD, Gilner JB, Zuckerwise LC. Placenta accreta spectrum. Obstet Gynecol 2023; 142 (01) 31-50
  • 3 Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR. Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine. Placenta accreta spectrum. Am J Obstet Gynecol 2018; 219 (06) B2-B16
  • 4 Silver RM, Branch DW. Placenta accreta spectrum. N Engl J Med 2018; 378 (16) 1529-1536
  • 5 Silver RM, Fox KA, Barton JR. et al. Center of excellence for placenta accreta. Am J Obstet Gynecol 2015; 212 (05) 561-568
  • 6 Esakoff TF, Handler SJ, Granados JM, Caughey AB. PAMUS: placenta accreta management across the United States. J Matern Fetal Neonatal Med 2012; 25 (06) 761-765
  • 7 van Beekhuizen HJ, Stefanovic V, Schwickert A. et al; International Society of Placenta Accreta Spectrum (IS-PAS) group. A multicenter observational survey of management strategies in 442 pregnancies with suspected placenta accreta spectrum. Acta Obstet Gynecol Scand 2021; 100 (Suppl. 01) 12-20
  • 8 Munoz JL, Blankenship LM, Ramsey PS, McCann GA. Importance of the gynecologic oncologist in management of cesarean hysterectomy for placenta accreta spectrum (PAS). Gynecol Oncol 2022; 166 (03) 460-464
  • 9 Levin G, Rottenstreich A, Benshushan A. et al. The role of supracervical hysterectomy in reducing blood products requirement in the management of placenta accreta: a case-control study. J Matern Fetal Neonatal Med 2020; 33 (15) 2522-2526
  • 10 Licon E, Vestal NL, Sangara RN. et al. Planned supracervical hysterectomy for surgical management of placenta accreta spectrum: a comparative study. Eur J Obstet Gynecol Reprod Biol 2021; 261: 249-251
  • 11 Vallejo A, Guo XM, Neuman MK, Youssefzadeh AC, Roman LD, Matsuo K. Cesarean hysterectomy for placenta accreta spectrum: 3-2-1 approach. Gynecol Oncol Rep 2024; 53: 101366
  • 12 Matsubara S, Takahashi H. Total vs. supracervical hysterectomy for placenta accreta spectrum disorders. J Matern Fetal Neonatal Med 2022; 35 (25) 5504-5505
  • 13 StataCorp. Stata: Release 18. Statistical software. College Station, TX: StataCorp LLC; 2023
  • 14 Erfani H, Fox KA, Clark SL. et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. Am J Obstet Gynecol 2019; 221 (04) 337.e1-337.e5
  • 15 Zhan Y, Lu E, Xu T. et al. Cesarean hysterectomy in pregnancies complicated with placenta previa accreta: a retrospective hospital-based study. BMC Pregnancy Childbirth 2024; 24 (01) 634
  • 16 Fishel Bartal M, Papanna R, Zacharias NM. et al. Planned versus unplanned delivery for placenta accreta spectrum. Am J Perinatol 2022; 39 (03) 252-258